Haisco Strikes $1.5 Billion NewCo Deal with Sentivera for Type 2 Inflammation Asset
Chinese drugmaker Haisco Pharmaceutical Group has struck another billion-dollar cross-border transaction, licensing ex-Greater China rights to a preclinical immunology asset to newly formed U.S. biotech Sentivera in a deal potentially worth more than $1.5 billion.
Haisco announced on August 25 that it has entered into an exclusive licensing agreement with Sentivera, a newly established U.S. biotechnology company founded by life-sciences investors Population Health Partners (PHP) and ARCH Venture Partners.
Under the agreement, Sentivera receives exclusive rights to develop, manufacture and commercialize one of Haisco’s internally discovered preclinical drugs worldwide outside Greater China.
The transaction carries a potential value exceeding $1.5 billion, comprising:
- $75.89 million in upfront payment and equity consideration in Sentivera;
- up to $1.46 billion in development, regulatory and commercial milestone payments; and
- tiered royalties ranging from the mid-single digits to low-double digits on post-launch net sales.
Importantly, Haisco retains an equity interest in Sentivera, giving the Chinese drugmaker potential participation in the future value of the new company beyond traditional milestones and royalties.
A NewCo Rather Than a Traditional License-Out
The structure distinguishes the Sentivera transaction from a conventional licensing agreement.
Haisco specifically described the arrangement as a NewCo partnership, with international venture investors establishing a new company around the licensed program. The structure potentially allows Haisco to monetize part of the asset’s value upfront while retaining exposure to future appreciation through its ownership stake.
Sentivera is being built by Population Health Partners, a life-sciences investment and company-building firm, and ARCH Venture Partners, one of the best-known U.S. venture firms involved in creating biotechnology companies.
For Haisco, this is not its first use of the model. In January, the company licensed global ex-Greater China rights to HSK39004 to AirNexis, another newly created U.S. biotech backed by a syndicate led by Frazier Life Sciences.
That transaction was worth up to $1.063 billion, including $40 million in cash upfront, $68 million in AirNexis equity and up to $955 million in milestones. AirNexis also launched with $200 million in committed financing.
The Sentivera agreement therefore represents another example of Chinese biopharma companies using U.S.-backed NewCos to globalize internally discovered drug candidates.
Targeting Type 2 Inflammatory Diseases
Haisco has disclosed relatively little about the identity of the drug transferred to Sentivera.
According to the company, the program is a core immunology asset designed to inhibit the development and progression of Type 2 inflammatory diseases. The candidate received clearance to begin clinical trials in China in August 2026.
Haisco said preclinical studies demonstrated strong anti-inflammatory activity and a favorable safety profile.
Type 2 inflammation is a central biological pathway underlying multiple immune-mediated disorders, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps and other allergic or inflammatory conditions. The commercial validation of the field has made new approaches capable of broadly suppressing Type 2 inflammatory signaling particularly attractive to global drug developers.
Could the Asset Be HSK60002?
While Haisco has not officially disclosed the asset’s code name, molecular target or modality, one intriguing possibility is HSK60002.
Haisco announced on August 12 that China’s National Medical Products Administration had cleared HSK60002 for clinical trials. The company described HSK60002 as a proprietary oral small-molecule drug intended to treat inflammatory diseases.
The timing is notable: Haisco’s Sentivera announcement says the licensed asset received China IND clearance this month, closely matching the August 12 clearance of HSK60002.
Haisco’s regulatory disclosure also states that HSK60002 demonstrated significant pharmacological activity in relevant preclinical animal models and has a clearly defined mechanism of action.
That circumstantial evidence has fueled industry speculation that HSK60002 could be the program licensed to Sentivera.
More specifically, some Chinese biotech industry observers have suggested that HSK60002 may be a STAT6-targeting PROTAC (proteolysis-targeting chimera).
Such a mechanism would make biological sense in the context of Type 2 inflammation. STAT6 is a critical downstream signaling protein for the cytokines IL-4 and IL-13, which play central roles in Type 2 inflammatory diseases. Targeted degradation of STAT6 could potentially suppress signaling downstream of both cytokines and provide an oral alternative to injectable biologics targeting the same inflammatory axis.
However, this identification remains unconfirmed. Neither Haisco nor Sentivera has publicly stated that the licensed candidate is HSK60002, nor have they confirmed that the asset targets STAT6 or uses a PROTAC modality. Until additional company or clinical-trial disclosures emerge, the connection should be treated as speculation.
Haisco’s Remarkable 2026 Deal-Making Run
The Sentivera transaction adds to an unusually active year of international business development for Haisco.
In January, Haisco transferred ex-Greater China rights to the PDE3/4 inhibitor HSK39004 to AirNexis in a deal worth up to $1.063 billion.
In April, Haisco signed an exclusive licensing agreement with AbbVie covering its Nav1.8 inhibitor program for pain. Haisco received $30 million upfront and is eligible for up to $715 million in additional milestones, plus royalties.
Then in May, Haisco entered a broad research and licensing collaboration with Eli Lilly involving as many as five innovative target programs. The agreement provides Haisco with up to $87 million in upfront and near-term payments and nearly $3 billion in potential additional milestones.
In June, Haisco licensed HSK42360 and HSK39297 to Nuvectis. Haisco received $40 million in upfront and near-term consideration and is eligible for up to $1.421 billion in additional milestones, plus royalties.
The Sentivera transaction therefore appears to be Haisco’s fifth major international partnering transaction announced in 2026, while also marking the company’s second major NewCo-style partnership following AirNexis.
Together, these transactions have generated billions of dollars in potential deal value and highlight Haisco’s rapid transformation from a primarily China-focused pharmaceutical company into an increasingly important source of globally licensed innovative medicines.
China-to-U.S. NewCo Model Gains Momentum
The Sentivera transaction is also notable for what it says about the evolution of China-to-global biotech partnering.
Rather than simply selling overseas rights to an established multinational pharmaceutical company, Chinese developers increasingly have the option of partnering with specialist life-sciences investors to create dedicated Western companies around individual assets.
For Haisco, such structures offer several potential advantages: immediate cash, external financing for overseas clinical development, access to experienced U.S. biotech investors and management teams, and continued participation in the asset’s upside through equity ownership.
Sentivera also gains a potentially differentiated immunology program that has already completed substantial preclinical work and obtained permission to enter human studies in China.
If speculation connecting the program to HSK60002 — and particularly to STAT6 degradation — is ultimately confirmed, the deal could attract considerably more attention given the intense global competition around Type 2 inflammation and the potential for oral medicines to challenge established injectable biologics.
For now, Haisco is keeping the molecular identity of its latest billion-dollar export under wraps. But the size of the Sentivera deal — and the participation of experienced biotech investors such as ARCH Venture Partners and Population Health Partners — suggests significant confidence in the program’s potential.
References
- Haisco Pharmaceutical Group. “Haisco enters into Exclusive License Agreement with new US venture founded by Population Health Partners and ARCH Venture Partners.” PR Newswire, August 25, 2026.
https://www.prnewswire.com/news-releases/haisco-enters-into-exclusive-license-agreement-with-new-us-venture-founded-by-population-health-partners-and-arch-venture-partners-302859307.html - Beijing Business Today. “Haisco HSK60002 Tablets Approved for Clinical Trials.” August 12, 2026.
https://www.bbtnews.com.cn/2026/0812/602012.shtml - Haisco Pharmaceutical Group. “Haisco Grants Global Rights of Innovative Drug HSK39004 to AirNexis in Deal Exceeding USD 1 Billion.” PR Newswire, January 12, 2026.
https://www.prnewswire.com/news-releases/haisco-grants-global-rights-of-innovative-drug-hsk39004-to-airnexis-in-deal-exceeding-usd-1-billion-302657951.html - Haisco Pharmaceutical Group. “Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain.” April 2026.
https://www.prnewswire.com/news-releases/haisco-enters-into-exclusive-license-agreement-with-abbvie-to-develop-novel-medicines-for-pain-302425918.html - Haisco Pharmaceutical Group. “Haisco Announces Licensing and Research Collaboration Agreement with Lilly to Develop Innovative Medicines Across Multiple Therapeutic Areas.” PR Newswire, June 1, 2026.
https://www.prnewswire.com/news-releases/haisco-announces-licensing-and-research-collaboration-agreement-with-lilly-to-develop-innovative-medicines-across-multiple-therapeutic-areas-302786957.html - Haisco Pharmaceutical Group. “Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement Indications.” PR Newswire, June 23, 2026.
https://www.prnewswire.com/news-releases/haisco-enters-into-exclusive-license-agreement-with-nuvectis-for-two-drug-candidates-in-oncology-and-complement-indications-302807803.html
